Admin
Categories
- alectinib – Alecensa from Chugai – Roche – GenenTech
- Anaplastic Large-Cell Lymphomas
- ASP3026 from Astellas
- Brain metastases
- brigatinib-Alunbrig from Takeda
- CEP-37440
- ceritinib – Zykadia from Novartis
- crizotinib – Xalkori from Pfizer
- Experiences
- Glioblastomas
- Imunotherapies
- JH-VIII-157-02
- lorlatinib – Lorbrena by Pfizer
- Lung cancer
- Neuroblastomas
- NMS-E628
- PLB1003 – Beijing Pearl Biotechnology
- Potential Treatments
- Regulatory applications & approvals
- Research
- Resistance to treatment
- RXDX-101 – entrectinib – by Ignyta
- Side Effects
- TPX-0005: TP Therapeutics
- TSR-011 from Tesaro
- Uncategorized
- X-396 – ensartinib from Xcovrery
Category Archives: Lung cancer
Patients can live a median of 6.8 years after stage 4 diagnosis
A study of 110 patients at the University of Colorado found that 50% of patients live 6.8 years or longer. These were patients who had access to multiple ALK inhibitors through clinical trials at that research University. That University also … Continue reading
Impact of EML4-ALK Variants on resistance
As of April 20, 2018 Study of 2 groups of patients. Group A = 129 patients, Group B = 577 patients. The most frequent variants were Variant 1 (43%) and Variant 3 (40%). “ALK resistance mutations were significantly more common … Continue reading
Liquid Biopsy can be used to track evolution of resistance
As of January 23, 2018 and March 29, 2018: Plasma genotyping by Next Generation Sequencing (Liquid Biopsy) can be used to track evolution of resistance to various ALK inhibitors. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785105/ https://www.ncbi.nlm.nih.gov/pubmed/29599410
Posted in Lung cancer, Research
Leave a comment